Skip to main content

Researchers develop a new class of covalent inhibitor for a protein involved in brain diseases

Scientific
17 May 18

Images

Participants

Image
Emeritus Professor
Tel.+34 93 40 37125
Image
Postdoctoral Fellow
Tel.+34 93 40 37127
Image
Alumni - Research Associate
Tel.+34 93 40 37127
Image
Alumni - Research Associate
Tel.+34 93 40 37127

Contact

Image
Communication Officer
Tel.+34 93 40 37255

For the scientific community, the protein POP (prolyl oligopeptidase) is an attractive therapeutic target for the treatment of cognitive and neurodegenerative disorders.

Scientists at IRB Barcelona have developed the first POP inhibitors that are irreversible, selective and brain-permeable.

An article published in Cell Chemical Biology by scientists at the Institute for Research in Biomedicine (IRB Barcelona) describes a new class of prolyl oligopeptidase (POP) inhibitors. Found mostly in the brain, POP has emerged as an “attractive·” therapeutic target for the treatment of several cognitive and neurodegenerative disorders, such as Parkinson’s disease and schizophrenia.

Most POP inhibitors developed to date have a short half-life in blood, do not show sufficient selectivity for the protein, and do not cross the blood-brain barrier (which protects the brain), thus limiting their potential as drugs.

Work done by IRB Barcelona postdoctoral fellow Salvador Guardiola describes the first class of POP inhibitor characterised by long half-life, selectivity and capacity to enter the brain. The Design, Synthesis and Structure of Peptides and Proteins lab, headed by Ernest Giralt, has generated and characterised a family of 15 modified peptides (small proteins), called peptidomimetics, which have shown promising results.

"Natural peptides are not stable in tissues and have relatively weak activity. In contrast, if we modify them with synthetic amino acids and introduce functional groups designed to react with the therapeutic target, we can achieve peptides that are much more active and efficient," explains Guardiola.

At low concentrations, these new peptides inhibit POP in a rapid, specific and sustained manner, both in the isolated enzyme and in human intact cells. In addition, they are highly selective for two proteases that are similar to POP (DPPIV and FAP) and show a high capacity to cross the blood-brain barrier, say the researchers.

"These inhibitors pave the way for the development of new treatments for diseases of the central nervous system and will also contribute to studies on the role of POP in these disorders and to the  development of inhibitors of other proteases," explains  Giralt, who is also a senior professor at the University of Barcelona (UB).

This study has been funded by the Ministry of Economy and Competitiveness, ERDFs, and the Catalan government. It has involved the UB’s Nuclear Magnetic Resonance Unit, IRB Barcelona’s Mass Spectrometry and Proteomics Facility, and the Barcelona Supercomputing Center. The work was done in collaboration with scientists at the University of Glasgow (Scotland, UK), the Utrecht Institute for Pharmaceutical Sciences (the Netherlands,) and the biotech Iproteos, a spin-off from IRB Barcelona and the UB.

 

More about Ernest Giralt's research: "The power of the medicinal chemistry" - Meet Our Scientists

 

Reference article:

Salvador Guardiola, Roger Prades, Laura Mendieta, Arwin J. Brouwer, Jelle Streefkerk, Laura Nevola, Teresa Tarragó, Rob M. J. Liskamp, Ernest Giralt

Targeted covalent inhibition of prolyl oligopeptidase (POP): discovery of sulfonylfluoride peptidomimetics

Cell Chemical Biology (2018) DOI:  10.1016/j.chembiol.2018.04.013

 

About IRB Barcelona

Created in 2005 by the Generalitat de Catalunya (Government of Catalonia) and University of Barcelona, IRB Barcelona is a Severo Ochoa Centre of Excellence, a seal that was awarded in 2011. The institute is devoted to conducting research of excellence in biomedicine and to transferring results to clinical practice, thus improving people’s quality of life, while simultaneously promoting the training of outstanding researchers, technology transfer, and public communication of science. Its 27 laboratories and eight core facilities address basic questions in biology and are orientated to diseases such as cancer, metastasis, Alzheimer’s, diabetes, and rare conditions. IRB Barcelona is an international centre that hosts 400 employees and more than 30 nationalities. It is located in the Barcelona Science Park. IRB Barcelona is a CERCA center, and a member of the Barcelona Institute of Science and Technology (BIST).